Dr. Zervas has deep experience with target identification including contributing to a novel three-phased approach using publicly available human transcriptomic data sets to identify and prioritize targets relevant to PTSD. This work was designed to be publicly available to serve the PTSD community and is currently under revision at Frontiers in Drug Discovery (Zervas et al., 2025). In addition, Dr. Zervas led efforts while at Amgen, which involved an international collaboration he established between Brigham and Women’s Hospital, Amgen, and deCODE Genetics (Iceland), using human genetics as a source to identify potential targets for Parkinson’s Disease. In both scenarios, putative drug targets were to be assessed with well-designed in vitro assays.